Special Issue "Tuberculosis Vaccines"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 October 2013)
Prof. Dr. Chinnaswamy Jagannath (Website)
Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, 6400 Fannin Street, MSB 2.200, Houston, TX 77030, USA
Interests: vaccines for tuberculosis; TLR signaling and adjuvants; Th1 immunity and T cells; Dendritic cells and macrophages-pathogen survival
Prof. Dr. Abu Salim Mustafa (Website)
Department of Microbiology, Faculty of Medicine, Kuwait University PO Box 24923, Safat 13110, Kuwait
Fax: +965 25332719
Interests: Tuberculosis; vaccines; immunodiagnosis; immuno-pathogenesis
Tuberculosis is a major health problem of global concern. According to estimates from the World Health Organization, one-third of the world population is infected with Mycobacterium tuberculosis, over 9 million people develop active disease and 2 million people die of tuberculosis each year. To immunize against tuberculosis, routine vaccination with Mycobacterium bovis BCG is practiced in many countries. Although, BCG vaccine offers some protection against childhood tuberculosis and severe forms of the disease in adults, it has failed to provide consistent protection against pulmonary disease in adults, which is the major manifestation of tuberculosis. Investigators are attempting to develop improved vaccines against tuberculosis by genetic manipulation of BCG, identifying M. tuberculosis auxotroph and protein antigens as subunit vaccines, etc. This special issue on “Tuberculosis Vaccines” will highlight leading developments in the vaccine technology, including but not limited to, genetically modified BCG, M. tuberculosis-derived vaccines, subunit (proteins/peptide, DNA and recombinant) vaccines, and their validation in animal models. Novel mechanisms of enhancing vaccine efficacy are also welcome including research on adjuvants and biomarkers of protection against tuberculosis. The special issue will be a mix of original research articles, and mini reviews. The main focus of this special issue is to present cutting edge research and recent developments in vaccines, which can prevent tuberculosis in mankind.
We look forward to reading your contributions
Prof. Dr. Chinnaswamy Jagannath
Prof. Dr. Abu Salim Mustafa
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- genetically modified BCG
- M. tuberculosis-derived vaccines
- subunit and peptide-based vaccines
- DNA vaccines
- recombinant-vector based vaccines
- adjuvants for vaccine delivery
- biomarkers of protection and novel mechanisms for enhancing vaccine efficacy